Dion F. Coakley
No más puestos en curso
Perfil
Dion F.
Coakley worked as a Director of Clinical Research at Gilead Sciences, Inc., Vice President of Clinical Research at Virobay, Inc., Global Vice President of Clinical Operations at Hyperion Therapeutics, Inc., and as a Principal at Burroughs Wellcome.
Coakley holds a doctorate from the University of Washington and an undergraduate degree from The University of Arkansas.
Antiguos cargos conocidos de Dion F. Coakley.
| Empresas | Cargo | Fin |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
| Burroughs Wellcome | Corporate Officer/Principal | - |
| HYPERION THERAPEUTICS INC | Director Técnico/Científico/I+D | - |
Virobay, Inc.
 Virobay, Inc. Pharmaceuticals: MajorHealth Technology Virobay, Inc. develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases. It utilize cysteine cathepsin platform for the development and commercialization of novel drugs. The firm's research & development activities focuses on neuropathic pain, autoimmune diseases and liver fibrosis. The company was founded by Robert F. G. Booth on May 18, 2006 and is headquartered in Menlo Park, CA. | Director Técnico/Científico/I+D | - |
Formación de Dion F. Coakley.
| University of Washington | Doctorate Degree |
| The University of Arkansas | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Virobay, Inc.
Virobay, Inc. Pharmaceuticals: MajorHealth Technology Virobay, Inc. develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases. It utilize cysteine cathepsin platform for the development and commercialization of novel drugs. The firm's research & development activities focuses on neuropathic pain, autoimmune diseases and liver fibrosis. The company was founded by Robert F. G. Booth on May 18, 2006 and is headquartered in Menlo Park, CA. | Health Technology |
| Burroughs Wellcome | |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Dion F. Coakley
